Cicada Variant (BA.3.2): Symptoms, Spread, Risks & What You Need to Know

What is the Cicada Variant (BA.3.2)?

The Cicada Variant (BA.3.2) is an emerging sub-lineage of the virus that causes COVID-19. It is associated with mutations in the SARS-CoV-2 and is believed to be part of the broader Omicron variant family, which has dominated global infections in recent years.

It is important to note that the term “Cicada Variant” is informal and not an officially recognized name by global health authorities. The scientific classification BA.3.2 is used to identify this subvariant within the Omicron lineage.

Like other COVID-19 variants, BA.3.2 has emerged due to genetic mutations over time. Viruses naturally evolve as they spread, and some mutations can affect how easily a variant transmits or how it interacts with existing immunity. However, as of now, there is limited variant-specific data, and much of what is understood about BA.3.2 is based on patterns observed in similar Omicron subvariants.

How Do COVID-19 Variants Like BA.3.2 Emerge?

To understand the Cicada Variant better, it helps to know how variants of COVID-19 develop.

Viruses such as SARS-CoV-2 continuously change through a process called mutation. Each time the virus replicates inside the body, small changes can occur in its genetic material.

Over time:

• Some mutations have no impact
• Others may make the virus spread more easily
• A few can help it partially evade immunity

When a group of mutations becomes distinct, it is classified as a new variant or subvariant.

The Omicron variant itself has multiple sub-lineages (such as BA.1, BA.2, BA.5), and BA.3.2 is believed to be one such offshoot. This ongoing evolution is why new variant names continue to appear in public discussions.

Why is it Called the “Cicada Variant”?

The name “Cicada Variant” is not part of any official naming system. Organizations like the World Health Organization use standardized labels such as Alpha, Delta, and Omicron to maintain clarity and avoid confusion.

The term “Cicada” appears to have originated from:

• Media coverage
• Social media discussions
• Informal naming trends

While such names can make complex scientific terms easier to remember, they can also create misunderstandings if not properly explained.

For clarity:

• Cicada Variant = informal/media name
• BA.3.2 = scientific classification
• Lineage = Omicron subvariant

Symptoms of Cicada Variant (BA.3.2)

The symptoms associated with the Cicada Variant are largely consistent with other Omicron subvariants. In most cases, the illness tends to be mild, particularly in individuals who have been vaccinated or previously infected.

Common Symptoms

• Fever or mild temperature elevation
• Sore throat
• Runny or blocked nose
• Dry cough
• Fatigue or weakness
• Headache
• Muscle or body aches

Additional Symptoms Seen in Some Cases

• Loss of taste or smell (less frequent than earlier variants)
• Mild gastrointestinal symptoms such as nausea
• Slight shortness of breath during exertion

In many individuals, these symptoms may resemble a common cold or seasonal flu, which can make early identification difficult without testing.

Are Symptoms Different from Previous Variants?

Compared to earlier variants like Delta, Omicron subvariants—including BA.3.2—tend to:

• Affect the upper respiratory tract more than the lungs
• Cause milder but more widespread infections
• Present with cold-like symptoms rather than severe pneumonia

However, symptom intensity can vary based on:

• Age
• Immunity level
• Presence of underlying health conditions

Severe Symptoms to Watch For

Although most cases are mild, certain symptoms require immediate medical attention:

• Difficulty breathing
• Persistent chest pain or tightness
• Sudden confusion or drowsiness
• Bluish lips or low oxygen saturation

These signs may indicate complications and should not be ignored.

How Does the Cicada Variant Spread?

The Cicada Variant spreads in the same way as other forms of COVID-19, primarily through respiratory transmission.

Main Modes of Spread

1. Respiratory Droplets

When an infected person coughs, sneezes, speaks, or even breathes, tiny droplets containing the virus are released into the air.

2. Airborne (Aerosol) Transmission

In enclosed or poorly ventilated spaces, smaller particles can remain suspended in the air for longer periods, increasing the risk of transmission.

3. Close Contact

Spending time in close proximity to an infected individual significantly raises the likelihood of infection.

Is BA.3.2 More Contagious?

While specific data on BA.3.2 is still evolving, subvariants of the Omicron variant are generally known for:

• Higher transmissibility compared to earlier variants
• Faster spread in densely populated settings
• Increased ability to infect individuals with prior immunity

This means that even if symptoms are mild, the variant can still spread quickly within communities.

Is the Cicada Variant More Severe?

Current observations suggest that the Cicada Variant (BA.3.2) does not appear to cause more severe disease than other Omicron subvariants.

What We Know So Far

• Most infections are mild to moderate
• Hospitalization rates are not significantly higher overall
• Vaccinated individuals typically experience shorter and less severe illness

Why Many Cases Are Milder

Several factors contribute to this trend:

1. Pre-existing Immunity

A large portion of the population has immunity due to:

• Vaccination
• Previous COVID-19 infection

This helps reduce the severity of illness.

2. Virus Evolution

Over time, viruses may evolve to spread more easily but cause less severe disease, allowing them to infect more hosts.

3. Improved Medical Care

Healthcare systems are now better equipped to:

• Diagnose early
• Manage symptoms effectively
• Prevent complications

Important Consideration

Even if a variant is considered “mild” at the population level, it can still pose significant risks for:

• Older adults
• Individuals with chronic conditions (such as diabetes, heart disease, or lung disorders)
• Immunocompromised individuals

For these groups, even a mild infection can lead to complications if not managed properly.

Who is at Higher Risk from the Cicada Variant?

While most infections linked to the Cicada Variant (BA.3.2) tend to be mild, certain groups remain more vulnerable to complications from COVID-19.

High-Risk Groups Include:

• Older adults (60+ years)
• Individuals with chronic conditions such as:
  • Diabetes
  • Heart disease
  • Lung disorders (e.g., asthma, COPD)
• People with weakened immune systems
• Patients undergoing cancer treatment or organ transplants
• Pregnant women (require additional monitoring)

For these individuals, even a seemingly mild infection can progress and may require closer medical supervision.

Diagnosis and Testing

Because the symptoms of the Cicada Variant are similar to other respiratory infections, testing remains the most reliable way to confirm infection.

Common Testing Methods

1. RT-PCR Test

• Considered the gold standard for detecting SARS-CoV-2
• Highly accurate
• Recommended for symptomatic individuals or high-risk patients

2. Rapid Antigen Test (RAT)

• Provides quicker results
• Useful for early detection, especially in community settings
• May require confirmation with RT-PCR in some cases

When Should You Get Tested?

• If you develop symptoms such as fever, cough, or sore throat
• After close contact with a confirmed COVID-19 case
• Before visiting high-risk individuals or healthcare facilities

Treatment and Management

Most cases of the Cicada Variant can be managed with supportive care at home, especially if symptoms are mild.

Home Care for Mild Cases

• Adequate rest
• Hydration (fluids, soups)
• Paracetamol for fever and body aches (as advised by a doctor)
• Monitoring oxygen levels using a pulse oximeter

Medical Treatment (When Needed)

In moderate to severe cases, treatment may include:

• Antiviral medications (as prescribed)
• Oxygen support
• Hospital care in case of complications

Recovery Timeline

For most individuals:

• Symptoms improve within 3–7 days
• Full recovery typically occurs within 1–2 weeks

However, fatigue or mild cough may persist slightly longer in some cases.

Prevention Tips

Even with milder variants, prevention remains key to reducing spread and protecting vulnerable populations.

Effective Preventive Measures

1. Vaccination

Vaccines continue to provide strong protection against severe illness caused by COVID-19.

2. Hand Hygiene

• Wash hands regularly with soap and water
• Use alcohol-based sanitizers when needed

3. Mask Usage (Situational)

• Recommended in crowded indoor settings
• Particularly important for high-risk individuals

4. Ventilation

• Ensure good airflow in indoor spaces
• Avoid poorly ventilated, crowded environments

5. Stay Home if Unwell

• Avoid spreading infection to others
• Especially important if you have symptoms

Cicada Variant vs Omicron: Key Differences

Feature	Cicada Variant (BA.3.2)	Omicron (General)
Classification	Sub-lineage	Major variant
Naming	Informal	WHO-recognized
Symptoms	Similar to Omicron	Cold-like symptoms
Severity	Mild to moderate	Mild to moderate
Spread	Likely high	High

Key Insight:
The Cicada Variant behaves very similarly to other Omicron variant subvariants rather than representing a completely new threat.

Is the Cicada Variant Present in India?

As with many emerging subvariants of SARS-CoV-2, tracking is ongoing. Variants can appear in different regions as the virus evolves.

At present:

• There is limited publicly confirmed data specific to BA.3.2 spread
• However, Omicron subvariants continue to circulate globally, including in India

It is advisable to:

• Stay updated with official health advisories
• Follow preventive measures regardless of variant type

When to See a Doctor

Most cases can be managed at home, but medical attention is necessary if symptoms worsen.

Seek Immediate Care If You Experience:

• Difficulty breathing
• Oxygen saturation below 94%
• Persistent chest pain
• High fever lasting more than 3 days
• Severe weakness or confusion

Consult a Doctor If:

• You belong to a high-risk group
• Symptoms do not improve within a few days
• You are unsure about your condition

Early consultation can help prevent complications and ensure timely treatment.

Frequently Asked Questions (FAQs)

1. Is the Cicada Variant dangerous?

The Cicada Variant (BA.3.2) does not currently appear to be more dangerous than other Omicron subvariants. Most cases are mild, but high-risk individuals should remain cautious.

2. Are symptoms of the Cicada Variant different?

Symptoms are largely similar to other COVID-19 variants, including fever, sore throat, cough, and fatigue.

3. Do COVID-19 vaccines work against BA.3.2?

Yes, vaccines continue to offer protection against severe illness and complications caused by COVID-19, including newer subvariants.

4. How long does infection last?

Most people recover within 1–2 weeks, although mild symptoms like fatigue may last longer in some cases.

5. Should I be worried about new variants like BA.3.2?

While it is important to stay informed, there is no need for panic. Following basic precautions and staying vaccinated significantly reduces risk.

6. Can previously infected individuals get infected again?

Yes, reinfections are possible with new variants, but prior immunity often helps reduce severity.